AAM
ARQT icon

AMI Asset Management’s Arcutis Biotherapeutics ARQT Stock Holding History

AMI Asset Management’s Portfolio ARQT Stock Details ARQT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$1.2M Buy
50,863
+1,601
+3% +$40.9K 0.08% 45
2025
Q4 		$1.43M Sell
49,262
-46,829
-49% -$1.2M 0.08% 46
2025
Q3 		$1.81M Sell
96,091
-17,791
-16% -$281K 0.1% 39
2025
Q2 		$1.6M Sell
113,882
-94,839
-45% -$1.33M 0.09% 39
2025
Q1 		$3.26M Sell
208,721
-7,237
-3% -$102K 0.19% 39
2024
Q4 		$3.01M Sell
215,958
-7,723
-3% -$84.6K 0.16% 39
2024
Q3 		$2.08M Buy
223,681
+59,487
+36% +$587K 0.11% 42
2024
Q2 		$1.53M Sell
164,194
-181,045
-52% -$1.64M 0.08% 52
2024
Q1 		$3.42M Buy
+345,239
New +$2.58M 0.17% 57

Other funds holding ARQT

SCM
Suvretta Capital Management New York $3.69B AUM 86.67% 1-Year Est. Return
FLSM
Frazier Life Sciences Management Palo Alto, California $3.89B AUM 201.1% 1-Year Est. Return
BlackRock
BlackRock New York $5.7T AUM 30.48% 1-Year Est. Return
RCMNY
Rubric Capital Management (New York) New York $8.16B AUM 68.42% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
PCH
Polar Capital Holdings London, United Kingdom $22.9B AUM 115.26% 1-Year Est. Return
Jennison Associates
Jennison Associates New York $145B AUM 34.61% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
GGHC
Gilder Gagnon Howe & Co New York $8.34B AUM 46.58% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return